Gocovri vs. Rytary

• Are Gocovri and Rytary the Same Thing?
• What Are Possible Side Effects of Gocovri?
• What Are Possible Side Effects of Rytary?
• What Is Gocovri?
• What Is Rytary?
• What Drugs Interact with Gocovri?
• What Drugs Interact with Rytary?
• How Should Gocovri Be Taken?
• How Should Rytary Be Taken?

Gocovri (amantadine extended release capsules) and Rytary (carbidopa and levodopa) are used to treat abnormal/involuntary muscle movement (dyskinesia) in patients with Parkinson's disease.

Rytary is also used to treat post-encephalitic Parkinsonism and Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Gocovri is an antivirial and anti-Parkinson drug and Rytary is a combination an inhibitor of aromatic amino acid decarboxylation and an aromatic amino acid.

Side effects of Gocovri and Rytary that are similar include dizziness, dry mouth, constipation, and dizziness on standing (orthostatic hypotension).

Side effects of Gocovri that are different from Rytary include hallucinations, swelling of extremities, and falls.

Side effects of Rytary that are different from Gocovri include nausea, headache, insomnia, abnormal dreams, involuntary movements, anxiety, vomiting, and low blood pressure.

Gocovri may interact with other anticholinergic drugs, carbonic anhydrase inhibitors, sodium bicarbonate, alcohol, and "live" vaccines.

Rytary may interact with MAO inhibitors, phenothiazines, butyrophenones, risperidone, metoclopramide, isoniazid, iron salts, and multi-vitamins containing iron salts.

Common side effects of Gocovri include:

• hallucinations,
• dizziness,
• dry mouth,
• swelling of extremities,
• constipation,
• falls,
• and dizziness on standing (orthostatic hypotension).

Other side effects of Gocovri include:

• anxiety,
• insomnia,
• depression,
• abnormal dreams,
• confusion,
• headache,
• muscle cramps,
• nausea,
• vomiting,
• gait disturbance,
• bruising,
• urinary tract infection,
• changes in skin pigmentation,
• decreased appetite,
• blurred vision,
• cataracts,
• dry eyes,
• joint swelling,
• muscle spasms,
• benign prostatic hyperplasia (BPH),
• and cough.

Common side effects of Rytary include:

• nausea,
• dizziness,
• headache,
• insomnia,
• abnormal dreams,
• dry mouth,
• involuntary movements,
• anxiety,
• constipation,
• vomiting, and
• low blood pressure and dizziness upon standing (orthostatic hypotension)

Gocovri (amantadine extended release capsules) is an antivirial and anti-Parkinson drug indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Rytary (carbidopa and levodopa) is a combination an inhibitor of aromatic amino acid decarboxylation and an aromatic amino acid, used for the treatment of Parkinson's disease, post-encephalitic Parkinsonism, and Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Gocovri may interact with other anticholinergic drugs, carbonic anhydrase inhibitors, sodium bicarbonate, alcohol, and “live” vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Gocovri is not recommended for use during pregnancy; it may harm a fetus. Gocovri passes into breast milk but its effect on nursing infants is unknown. Gocovri may alter breast milk production or excretion. Consult your doctor before breastfeeding.

Rytary may interact with MAO inhibitors, phenothiazines, butyrophenones, risperidone, metoclopramide, isoniazid, iron salts, or multi-vitamins containing iron salts. Tell your doctor all medications and supplements you use. During pregnancy, Rytary should be used only if prescribed. These drugs may pass into breast milk. Consult your doctor before breastfeeding.

The initial daily dosage of Gocovri is 137 mg, administered orally once daily at bedtime. After one week, increase to the recommended dosage of 274 mg (two 137 mg capsules) once daily at bedtime.

The recommended starting dosage of Rytary is 23.75 mg/95 mg taken orally three times a day for the first 3 days. On the fourth day of treatment, the dosage of Rytary may be increased to 36.25 mg/145 mg taken three times a day.